HIGHLIGHTS
- who: Iwona Karwaciak and colleagues from the Laboratory of Epigenetics, Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland have published the paper: Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes, in the Journal: Molecules 2022, 3651 of 27/04/2022
- what: The authors show that inhibits the expression and secretion of IL-6 by monocytes activated by SARS-CoV-2 virus nucleocapsid protein and affects the activity of NF-κB and MEK/ERK signaling. The authors show that the antipsychotic drug chlorpromazine .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.